Heart Care Info - Heart Disease Prevention & Treatment

... and Demographic Predictors of Outcomes in Recent Onset Dilated Cardiomyopathy:: Results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 ...

DM Mc Namara, RC Starling, LT Cooper... - Journal of the American ..., 2011 - Elsevier The cohort of 373 persons was 38% female and 21% black, with a mean age of 45 14 years. At entry, 91% were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 82% were receiving beta-blockers, which increased to 92% and ...

In the multicenter IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study, subjects with a left ventricular ejection fraction (LVEF) of ≤0.40, fewer than 6 months of symptom duration, and an evaluation consistent with idiopathic dilated cardiomyopathy or myocarditis were enrolled. LVEF was reassessed at 6 months, and subjects were followed up for 4 years. LVEF and event-free survival were compared by race, sex, and clinical phenotype.

The cohort of 373 persons was 38% female and 21% black, with a mean age of 45 14 years. At entry, 91% were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 82% were receiving beta-blockers, which increased to 92% and 94% at 6 months. LVEF was 0.24 0.08 at entry and 0.40 0.12 at 6 months (mean increase: 17 13 ejection fraction units). Transplant-free survival at 1, 2, and 4 years was 94%, 92%, and 88%, respectively; survival free of heart failure hospitalization was 88%, 82%, and 78%, respectively. In analyses adjusted for sex, baseline LVEF, and blood pressure, LVEF at 6 months was significantly lower in blacks than in nonblacks (p = 0.02). Left ventricular end-diastolic diameter at presentation was the strongest predictor of LVEF at 6 months (p < 0.0001).